EFdA Diester Prodrug Suspensions for Extended HIV Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

EFdA, a nucleoside analog effective as an antiretroviral, has a high water solubility and short plasma concentration, limiting its duration of viral suppression when administered for HIV treatment or pre-exposure prophylaxis.

Innovation Solution

Development of EFdA diesters with reduced aqueous solubility, formulated as crystalline compounds in parenteral suspensions with pharmaceutically acceptable carriers, providing extended duration of viral suppression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If EFdA is administered as a nucleoside analog, then antiviral activity is achieved, but duration of viral suppression is limited due to short plasma concentration

Engineering Contradiction:

Improveduration of viral suppressionVSAvoidplasma concentration

Core Design Contradiction:

Duration of action of moving objectVSQuantity of substance

Solution Approach 1:

The patent modifies the chemical structure of EFdA by converting it into diester prodrugs with different physicochemical properties. These prodrugs have reduced water solubility and altered pharmacokinetics, enabling sustained release and extended duration of viral suppression compared to the parent compound

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The diester prodrugs serve as intermediary compounds that are converted in vivo to the active EFdA metabolite. This intermediate form allows the drug to be administered less frequently while maintaining therapeutic plasma concentrations over an extended period

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If EFdA is formulated with high water solubility, then ease of administration is improved, but duration of action is reduced due to rapid clearance

Engineering Contradiction:

Improveease of administrationVSAvoidduration of viral suppression

Core Design Contradiction:

Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent systematically alters the solubility parameter of EFdA by introducing ester groups at the 2'-position. The diester prodrugs exhibit significantly reduced water solubility compared to the parent compound, which correlates with extended plasma half-life and duration of action while maintaining parenteral administrability

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12569510B2Antiviral prodrugs and pharmaceutical compositions thereof

Publication Date: 2026.03.10 THE SCRIPPS RES INST

AI summary

Diesters of 4′-ethynyl-2-fluoro-2′-deoxyadenosine and aqueous parenteral suspensions thereof provide extended in vivo viral suppression of human immunodeficiency virus (HIV).